clinical trial · NCT05294731
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
BeiGene·phase2·recruiting·n = 146
B-cell MalignancyNon-Hodgkin LymphomaMantle Cell LymphomaChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaWaldenström MacroglobulinemiaMarginal Zone LymphomaFollicular LymphomaDLBCL UnclassifiableBGB-16673
brief summary
This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts
started
May 6, 2022
primary completion
Jan 31, 2029
completion
Jan 31, 2029
last updated
Apr 17, 2026
official title
A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Chinese Patients With B-Cell Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol